<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131314">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02125877</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670F2201</org_study_id>
    <nct_id>NCT02125877</nct_id>
  </id_info>
  <brief_title>Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)</brief_title>
  <official_title>A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>France: National Agency for the Safety of Medicines and Health Products (MSNA)</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Lebanon: Ministry of Public Health</authority>
    <authority>Saudi Arabia: Ministry of Health</authority>
    <authority>Saudi Arabia: Ethics Committee</authority>
    <authority>Thailand: Food and Drug Administration</authority>
    <authority>Malaysia: Ministry of Health</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Mexico: Ministry of Health</authority>
    <authority>Greece: Ministry of Health and Welfare</authority>
    <authority>Thailand: Ministry of Public Health</authority>
    <authority>Russia: Ethics Committee</authority>
    <authority>United Arab Emirates: Drug Control Department - Medicines and Pharmacy Control - Ministry of Health</authority>
    <authority>United Arab Emirates: General Authority for Health Services for Abu Dhabi</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the new film-coated tablet formulation to the currently approved dispersible tablet
      formulation with regards to overall safety, Gastrointestinal (GI) tolerability,
      palatability, satisfaction and compliance
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall safety</measure>
    <time_frame>Screening visit thru post-treatment period - 30 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>As measured by frequency and severity of adverse events (AEs) and changes in laboratory values from baseline (serum creatinine,creatinine clearance, Alanine aminotransferase (ALT), Aspartate aminotransferase  (AST), platelets, red blood cells (RBC) and white blood cell (WBC)) from day of patient's informed consent until 31 days after last dose of study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of selected GI AEs (Gastro-Intestinal Adverse Events)</measure>
    <time_frame>on-treatment period (Day 1 - safety follow-up) - 28 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>(diarrhea, constipation, nausea, vomiting, abdominal pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>week 1, 3, 13 and 21</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AUCtau, AUClast, Cmax, Tmax at week 1 and week 3 (only applies to PK subset A) C2hr and Ctrough at week 3, 13 and 21 for all study patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Domain scores of treatment satisfaction and palatability over time</measure>
    <time_frame>Week 2, 3, 13 and end of treatment (week 24 or within 7 days of last dose)</time_frame>
    <safety_issue>No</safety_issue>
    <description>analyses will be performed for both formulations for each domain score at scheduled visits (Week 2, Week 3, Week 13, visit 777 (end of treatment) and their absolute changes at Week 13 and 777 from Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly average of daily scores of GI diary</measure>
    <time_frame>Weekly (screening thru end of treatment visit) - 26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>weekly average scores of daily GI symptom scores: diarrhea, constipation, nausea, vomiting and abdominal pain, and weekly average frequencies of daily bowel movement, bowel movement related with diarrhea and accidental bowel movement will be summarized over time by descriptive statistics for both formulations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative consumed film-coated tablet (FCT)/dispersible tablet (DT) counts. Patient-reported medication consumption</measure>
    <time_frame>Daily (day 1/visit 3 - last visit) 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>For the daily compliance questionnaire, three dimensions of medication compliance: whether the study medication is consumed, when the medication is consumed, and whether the medication is consumed with or without food will be summarized over time by descriptive statistics for both formulations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Iron Overload Due to Transfusion-dependant Anemias</condition>
  <arm_group>
    <arm_group_label>deferasirox dispersible tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>deferasirox film-coated tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox dispersible tablet</intervention_name>
    <description>Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.</description>
    <arm_group_label>deferasirox dispersible tablet</arm_group_label>
    <other_name>ICL670, DT (dispersible tablet)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Defearisox film-coated tablet</intervention_name>
    <description>Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.</description>
    <arm_group_label>deferasirox film-coated tablet</arm_group_label>
    <other_name>ICL670, FCT (film-coated tablet)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged ≥ 10 years

          -  Patients with transfusion-dependent thalassemia and iron overload, requiring
             deferasirox DT at doses of ≥ 30 mg/kg/day as per the investigator's decision OR
             Patients with very low, low or intermediate (int) risk myelodysplastic syndrome (MDS)
             and iron overload, requiring deferasirox DT at doses of ≥ 20 mg/kg/day as per the
             investigator's decision.

          -  History of transfusion of at least 20 PRBC units and anticipated to be transfused
             with at least 8 units of PRBCs annually during the study

          -  Serum ferritin &gt; 1000 ng/mL, measured at screening Visit 1 and screening Visit 2 (the
             mean value will be used for eligibility criteria).

        Exclusion Criteria:

          -  Creatinine clearance below the contraindication limit in the locally approved
             prescribing information. Creatinine clearance will be estimated from serum creatinine
             at screening Visit 1 and screening Visit 2 and the mean value will be used for
             eligibility criteria.

          -  Serum creatinine &gt; 1.5 xULN at screening measured at screening Visit 1 and screening
             Visit 2 (the mean value will be used for eligibility criteria).

          -  ALT (SGPT) &gt; 5xULN, unless if LIC confirmed as &lt;10 mg Fe/dw within 6 months prior to
             screening visit 1.

          -  Significant proteinuria as indicated by a urinary protein/creatinine ratio &gt; 0.5
             mg/mg in a non-first void urine sample at screening Visit 1 or screening Visit 2.

          -  Patients with significant impaired gastrointestinal (GI) function or GI disease that
             may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel
             resection).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Oakland Onc Dept</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Oakland Onc Dept</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynne Neumayr</last_name>
      <phone>510-428-3651</phone>
      <email>lneumayr@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Elliott P. Vichinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County Onc Dept</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3874</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County Onc Dept</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3874</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brandy Gonzales</last_name>
      <phone>714-509-8824</phone>
      <email>bgonzales@choc.org</email>
    </contact>
    <investigator>
      <last_name>Geetha Puthenveetil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Onc Dept</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center 3</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Licciardi</last_name>
      <phone>312-563-3347</phone>
      <email>Nancy_Licciardi@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Jamile Shammo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Onc Dept</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Devin Muntz</last_name>
      <phone>312-227-4824</phone>
      <email>dmuntz@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Alexis Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston Department of Hematology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pamela Boardman</last_name>
      <phone>617-355-2901</phone>
      <email>pamela.boardman@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Ellis Neufeld</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College-Cornell University Onc Dept</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College-Cornell University Onc Dept</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Jimenez</last_name>
      <phone>212-746-3446</phone>
      <email>maj7002@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia Giardina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia Onc. Dept</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4399</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia Onc. Dept</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4399</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helen Stanley</last_name>
      <phone>267-426-5602</phone>
      <email>stanleyh1@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Janet L. Kwiatkowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille Cédex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hazmiyeh</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50589</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pulau Pinang</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>02990</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moskow</city>
        <state>Russia</state>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostov on Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dammam</city>
        <zip>15215</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dammam</city>
        <zip>40145</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jeddah</city>
        <zip>21589</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riyadh</city>
        <zip>11472</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Al Ain - Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dubai</city>
        <zip>9115</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>April 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron overload</keyword>
  <keyword>Chelation</keyword>
  <keyword>Thalassemia</keyword>
  <keyword>Myelodysplastic syndrome (MDS)</keyword>
  <keyword>Transfusional hemisiderosis</keyword>
  <keyword>Deferasirox</keyword>
  <keyword>ICL670</keyword>
  <keyword>Dispersible tablet</keyword>
  <keyword>Film-coated tablet</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
